8 years of historical data (2017–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Milestone Pharmaceuticals Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $146M | $147M | $72M | $168M | $274M | $197M | $253M | — | — |
| Enterprise Value | $175M | $176M | $110M | $163M | $161M | $125M | $133M | — | — |
| P/E Ratio → | -2.55 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 71.74 | 33.62 | 18.27 | — | — | — | — |
| P/B Ratio | 8.09 | 11.17 | 4.28 | 2.53 | 2.43 | 1.37 | 2.20 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 109.75 | 32.59 | 10.70 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have compressed from -1192.8% to -6109.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -277.6% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | 100.0% | — | — | — | — |
| Operating Margin | — | — | -6109.8% | -1192.8% | -287.2% | — | — | — | — |
| Net Profit Margin | — | — | -5968.5% | -1167.8% | -285.7% | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -277.6% | -277.6% | -143.6% | -65.3% | -33.5% | -38.7% | -185.0% | — | — |
| ROA | -55.1% | -55.1% | -79.7% | -60.1% | -31.8% | -36.6% | -52.2% | -40.1% | -29.3% |
| ROIC | -64.8% | -64.8% | -79.0% | -148.2% | -91.1% | -112.9% | — | — | — |
| ROCE | -62.2% | -62.2% | -89.6% | -65.8% | -33.5% | -39.2% | -58.3% | -43.5% | -31.8% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $29M ($55M total debt minus $25M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 4.17 | 4.17 | 3.09 | 0.04 | 0.01 | 0.01 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 2.24 | 2.27 | -0.08 | -1.01 | -0.50 | -1.04 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -23.92 | — | — | -69.85 | -22.30 | — | — |
Short-term solvency ratios and asset-utilisation metrics
Milestone Pharmaceuticals Inc.'s current ratio of 9.10x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 11.70x to 9.10x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.10 | 9.10 | 10.11 | 11.70 | 17.55 | 24.14 | 14.71 | 19.42 | 17.17 |
| Quick Ratio | 9.10 | 9.10 | 10.11 | 11.70 | 17.55 | 24.14 | 14.71 | 19.42 | 17.17 |
| Cash Ratio | 8.58 | 8.58 | 9.13 | 10.52 | 16.85 | 23.11 | 14.39 | 18.97 | 16.77 |
| Asset Turnover | — | — | 0.01 | 0.07 | 0.13 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 1405.62 | 88.55 | 11.75 | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Milestone Pharmaceuticals Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $62M | $43M | $42M | $42M | $29M | $16M | $24M | $24M |
Compare MIST with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| MISTYou | $146M | -2.6 | — | — | — | — | -277.6% | -64.8% | — |
| UTHR | $22B | 18.1 | 12.9 | 21.1 | 87.9% | 46.9% | 19.7% | 21.1% | — |
| ZLAB | $21B | -12.0 | — | — | 58.6% | -49.9% | -22.6% | -42.8% | — |
| AMRN | $6B | -3.5 | — | — | 35.6% | -40.2% | -15.8% | -18.7% | — |
| ALKS | $5B | 21.0 | 15.9 | 9571.4 | 86.3% | 17.2% | 14.7% | 14.9% | 0.2 |
| ADMA | $4B | 19.2 | 25.1 | 33.7 | 51.5% | 32.6% | 81.6% | 37.7% | 0.6 |
| ARQT | $3B | -207.5 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
| LQDA | $3B | -18.7 | — | — | 58.0% | -866.6% | -209.4% | -500.7% | — |
| SLGL | $3B | -241.3 | — | — | 98.0% | -104.1% | -31.4% | -41.5% | — |
| MLYS | $2B | -8.0 | — | — | — | — | -82.2% | -107.3% | — |
| ARDX | $2B | -25.2 | — | — | 90.3% | -10.1% | -36.2% | -10.8% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 8 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how MIST stacks up against sector leader United Therapeutics Corporation.
Start ComparisonMilestone Pharmaceuticals Inc.'s current P/E ratio is -2.6x. This places it at the 50th percentile of its historical range.
Milestone Pharmaceuticals Inc.'s return on equity (ROE) is -277.6%. The historical average is -123.9%.
Based on historical data, Milestone Pharmaceuticals Inc. is trading at a P/E of -2.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.